Jessica ChutterManaging Director, Chairman of Biotechnology Investment Banking, Morgan Stanley
Jessica Chutter is the managing director and chairman of Biotechnology Investment Banking atMorgan Stanley.
During Chutter’s 27-year career of building Morgan Stanley’s biotechnology franchise, she has been responsible for $22 billion of capital raising and $55 billion of strategic transactions. Recent transactions include advising Alkermes on its $960 million acquisition of EDT, Cubist on its $415 million acquisition of Adolor, Endo on its $2.9 billion acquisition of AMS and Pharmasset in its $11 billion sale to Gilead. She has also been involved in the creation of a new asset class involving royalty-backed debt (PhaRMA) where over $4 billion was raised.